Treatment of Advanced Clear-Cell Metastatic Renal Cell Carcinoma with Sarcomatoid Features
Clinical scenario
Advanced clear-cell metastatic renal cell carcinoma presenting with sarcomatoid features — a specific histological subtype that warrants a distinct first-line treatment approach.
In this setting, current guidance supports the use of immune checkpoint inhibitor combination therapy. Which specific combinations apply, how they are selected, and the full evidence-based regimen are detailed in the complete protocol…
Offer immune checkpoint inhibitor combination therapy for advanced clear cell metastatic RCC with sarcomatoid features.
Ipilimumab/nivolumab, axitinib/pembrolizumab and lenvatinib/pembrolizumab, avelumab/axitinib can all be recommended instead of VEFG-targeted therapy alone.